Surrey Heartlands

Joint Formulary & PAD

Loteprednol etabonate - Postoperative pain and inflammation (eye)

You are here : Home > Formulary Search > Loteprednol etabonate - Postoperative pain and inflammation (eye)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Eye drops
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important
Max 14 day treatment - supply from the Trust

Documentation

Guidelines (Local)
Loteprednol etabonate - APC briefing - March 2023.pdf

PAD Profile

ChemicalSubstance :
Loteprednol etabonate
Indication :
Postoperative pain and inflammation (eye)
Group Name :
Keywords :
Brand Names Include :
Lotemax
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Loteprednol etabonate is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Postoperative pain and inflammation (eye).

Committee Recommendations (1)

01 Mar 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) agrees that loteprednol etabonate eye drops  should only be used on a short-term basis (maximum of 2 weeks duration) to treat post-operative inflammation as per its product license.

Therefore, loteprednol etabonate  a RED traffic light status is agreed by APC.

Sufficient quantities should be supplied through secondary care as part of a package of post-operative care.”